Israeli company’s Moxo diagnostic assessment test provides uniquely actionable data on attention, hyperactivity, impulsivity and timing for people with ADHD.
While several other Israeli companies are pioneering treatment options for attention-deficit/hyperactivity disorder (ADHD), Nes Ziona-based NeuroTechnology Solutions has put its development efforts into Internet-based software technologies that help clinicians better diagnose and monitor attention problems.
The system, Moxo Analytics , has different versions for children and adults, and delivers scores on a range of developmental, cognitive and behavioral components of ADHD making it easier to decide how to help the person suffering from the disorder.
Moxo already has the European Union’s CE mark and was introduced in Israel nearly four years ago and now claims 40 percent of the market. Clinicians in Canada, Turkey, Poland, South Africa, Mexico and Spain are using it too, and other markets are on the horizon.
According to the ADHD Institute, the worldwide prevalence of ADHD is between 5.29 and 7.1 percent in people under 18 years old. It affects up to one in 20 American children, more often boys than girls, and often continues into adulthood.
More...
